On January 6, 2021 Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in January, 2021 (Press release, Molecular Partners, JAN 6, 2021, View Source [SID1234573572]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Presentation Details:
Event: H.C. Wainwright BioConnect 2021 Conference
Date/Time: Monday, January 11, 2021 at 6:00 a.m. ET (12:00 p.m. CET)
Event: Baader Helvea Swiss Equities Conference
Date/Time: Wednesday, January 13, 2021 at 1:00 p.m. CET (7:00 a.m. ET)
Event: JP Morgan 39th Annual Virtual Healthcare Conference
Date/Time: Thursday, January 14, 2021 at 7:30 a.m. ET (1:30 p.m. CET)
Conference Participation Details:
Event: The Octavian Seminar 2021
Date: Friday, January 15, 2021
All webcasted presentations will be made available on the Molecular Partners website.